Zydus Lifesciences resolves US patent dispute on bladder drug with $120 mn settlement

Under the settlement, Zydus and its US unit will also pay a pre-paid per-unit licensing fee on sales of its generic version of Mirabegron in the US from the agreement date until September 2027